JPWO2020008032A5 - - Google Patents

Claims (23)

A pharmaceutical composition comprising a reverse micelle system for use in the treatment of subjects exposed to radiation and / or in the prevention of radiation hazards in subjects at risk of exposure to radiation.
The reverse micelle system contains at least sterols, 50-90% acylglycerol, 1-20% lecithin, ethanol and water, and the weight ratio of lecithin to acylglycerol is 0.05-0.4.
A pharmaceutical composition in which the reverse micelle system does not contain a chelating agent. The pharmaceutical composition for use according to claim 1, wherein the reverse micelle system comprises manganese. The pharmaceutical composition for use according to claim 1 or 2, wherein the reverse micelle system comprises at least 300 μg / g of manganese. The pharmaceutical composition for use according to any one of claims 1 to 3, wherein the reverse micelle system contains 5 to 15% lecithin. The pharmaceutical for use according to any one of claims 1 to 4, comprising administering the pharmaceutical composition such that an effective amount of the reverse micelle system is administered to a subject at risk of radiation exposure. Composition . The pharmaceutical composition for use according to claim 5, comprising administering the pharmaceutical composition such that an effective amount of the inverted micelle system is administered to the subject prior to radiation therapy. Prior to radiation therapy for the treatment of cancer or prior to administration of a radioisotope for medical diagnosis, the pharmaceutical composition is administered such that an effective amount of the inverse micelle system is administered to the subject. The pharmaceutical composition for use according to claim 5, including the above. The pharmaceutical composition for use according to claim 7, wherein after radiation therapy for the treatment of cancer, cancer cells are more sensitive to said radiation therapy than non-cancerous cells. The pharmaceutical composition for use according to claim 5, comprising administering the pharmaceutical composition such that an effective amount of the inverted micelle system is administered to the subject prior to entering a military combat. The pharmaceutical composition for use according to claim 5, comprising administering the pharmaceutical composition such that an effective amount of the inverted micelle system is administered to the subject prior to a nuclear attack or accident. The pharmaceutical composition for use according to any one of claims 1 to 4, comprising administering the pharmaceutical composition such that an effective amount of the reverse micelle system is administered to a subject exposed to radiation. Things . The pharmaceutical composition for use according to claim 11, comprising administering the pharmaceutical composition such that an effective amount of the reverse micelle system is administered to a subject exposed to radiation therapy. The pharmaceutical for use according to claim 11, comprising administering the pharmaceutical composition such that an effective amount of the reverse micelle system is administered to a subject exposed to radiation therapy for the treatment of cancer. Composition . 13. The pharmaceutical composition for use according to claim 13, wherein the cancer cells are more sensitive to said radiation therapy than non-cancer cells. The pharmaceutical composition for use according to claim 11, comprising administering the pharmaceutical composition such that an effective amount of the inverted micelle system is administered to the subject after a military combat. The pharmaceutical composition for use according to claim 11, comprising administering the pharmaceutical composition such that an effective amount of the inverted micelle system is administered to the subject after a nuclear attack or accident. The pharmaceutical for use according to claim 11 , wherein the pharmaceutical composition is administered to a subject exposed to a radioisotope for medical diagnosis so that an effective amount of the reverse micelle system is administered. Composition . The pharmaceutical composition for use according to any one of claims 1 to 17, wherein the reverse micelle system contains manganese, wherein the manganese is evenly distributed to all cells of the body. The pharmaceutical composition for use according to any one of claims 1 to 18, wherein the pharmaceutical composition is administered transmucosally. The reverse micelle system is DTPA, bisphosphonate, prusian blue, EDTA, trientine, D-penicillamine, deferroxamine, BAL, DMSA, DMPS, phytic acid, hydroxypyridonate (HOPO), mercaptoacetyltriglycine (MAG3), chelated. The pharmaceutical composition for use according to any one of claims 1 to 19, which does not contain peptides, derivatives thereof and combinations thereof . A reverse micellar system containing at least sterols, 50-90% acylglycerol, 1-20% lecithin, ethanol and water, the weight ratio of lecithin to acylglycerol is 0.05-0.4, said reverse micellar system. , Metal-free, chelating agent-free, reverse micelle system. 21. The inverse micelle system of claim 21, comprising 5-15% lecithin. The reverse micelle system is DTPA, bisphosphonate, prusian blue, EDTA, trientine, D-penicillamine, deferroxamine, BAL, DMSA, DMPS, phytic acid, hydroxypyridonate (HOPO), mercaptoacetyltriglycine (MAG3), chelated. The inverted micelle system according to claim 21 or 22, which does not contain peptides, derivatives thereof and combinations thereof.